MX2022002062A - Derivados heterociclicos del pirazol como inhibidores de los receptores de tirosina cinasa tipo iii. - Google Patents
Derivados heterociclicos del pirazol como inhibidores de los receptores de tirosina cinasa tipo iii.Info
- Publication number
- MX2022002062A MX2022002062A MX2022002062A MX2022002062A MX2022002062A MX 2022002062 A MX2022002062 A MX 2022002062A MX 2022002062 A MX2022002062 A MX 2022002062A MX 2022002062 A MX2022002062 A MX 2022002062A MX 2022002062 A MX2022002062 A MX 2022002062A
- Authority
- MX
- Mexico
- Prior art keywords
- kinases
- diseases
- pyrazole
- inhibitors
- pdgfr
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 title 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 title 1
- WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical class C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 6
- 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 abstract 3
- 101000932478 Homo sapiens Receptor-type tyrosine-protein kinase FLT3 Proteins 0.000 abstract 3
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 abstract 3
- 102100020718 Receptor-type tyrosine-protein kinase FLT3 Human genes 0.000 abstract 3
- 201000010099 disease Diseases 0.000 abstract 3
- 208000035475 disorder Diseases 0.000 abstract 3
- 230000001404 mediated effect Effects 0.000 abstract 3
- 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 abstract 2
- 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 2
- 102000001253 Protein Kinase Human genes 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000020233 phosphotransferase Human genes 0.000 abstract 2
- 108060006633 protein kinase Proteins 0.000 abstract 2
- 102000027426 receptor tyrosine kinases Human genes 0.000 abstract 2
- 108091008598 receptor tyrosine kinases Proteins 0.000 abstract 2
- 208000023275 Autoimmune disease Diseases 0.000 abstract 1
- 108010046938 Macrophage Colony-Stimulating Factor Proteins 0.000 abstract 1
- 102100028123 Macrophage colony-stimulating factor 1 Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000019664 bone resorption disease Diseases 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 238000011865 proteolysis targeting chimera technique Methods 0.000 abstract 1
- 229940124823 proteolysis targeting chimeric molecule Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 108010026668 snake venom protein C activator Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4162—1,2-Diazoles condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/541—Non-condensed thiazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962891097P | 2019-08-23 | 2019-08-23 | |
| PCT/US2020/047552 WO2021041276A1 (en) | 2019-08-23 | 2020-08-22 | Heterocyclic pyrazole derivatives as type iii receptor tyrosine kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2022002062A true MX2022002062A (es) | 2022-04-25 |
Family
ID=74685735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2022002062A MX2022002062A (es) | 2019-08-23 | 2020-08-22 | Derivados heterociclicos del pirazol como inhibidores de los receptores de tirosina cinasa tipo iii. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12448394B2 (https=) |
| EP (1) | EP4017853A4 (https=) |
| JP (1) | JP7651557B2 (https=) |
| KR (1) | KR20220051365A (https=) |
| CN (1) | CN114502553B (https=) |
| AU (1) | AU2020337883B2 (https=) |
| BR (1) | BR112022003383A2 (https=) |
| CA (1) | CA3151821A1 (https=) |
| MX (1) | MX2022002062A (https=) |
| TW (1) | TWI759829B (https=) |
| WO (1) | WO2021041276A1 (https=) |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2323952T3 (es) | 2002-05-15 | 2009-07-28 | Janssen Pharmaceutica Nv | 3-aminopirazol triciclicos sustituidos en n como inhibidores receptores de pdfg. |
| RU2425677C2 (ru) | 2005-01-21 | 2011-08-10 | Астекс Терапьютикс Лимитед | Соединения, предназначенные для использования в фармацевтике |
| CN101146532B (zh) | 2005-01-21 | 2012-05-09 | 阿斯泰克斯治疗有限公司 | 药物化合物 |
| JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体 |
| JP2010505859A (ja) | 2006-10-06 | 2010-02-25 | アイアールエム・リミテッド・ライアビリティ・カンパニー | タンパク質キナーゼ阻害剤およびそれを使用するための方法 |
| KR101122481B1 (ko) | 2007-05-04 | 2012-02-29 | 아이알엠 엘엘씨 | Ｃ-ｋｉｔ 및 ｐｄｇｆｒ 키나제 억제제로서의 피리미딘 유도체 및 조성물 |
| EA024729B1 (ru) * | 2009-11-13 | 2016-10-31 | Джиноско | Киназные ингибиторы |
| GB201007286D0 (en) * | 2010-04-30 | 2010-06-16 | Astex Therapeutics Ltd | New compounds |
| UA112425C2 (uk) | 2010-12-13 | 2016-09-12 | Еррей Біофарма Інк. | ЗАМІЩЕНІ N-(1H-ІНДАЗОЛ-4-ІЛ)ІМІДАЗО[1,2-a]ПІРИДИН-3-КАРБОКСАМІДНІ СПОЛУКИ ЯК ІНГІБІТОРИ РЕЦЕПТОРНОЇ ТИРОЗИНКІНАЗИ ІІІ ТИПУ |
| US8877763B2 (en) * | 2012-03-22 | 2014-11-04 | Genosco | Substituted pyridopyrimidine compounds and their use as FLT3 inhibitors |
| GB201205669D0 (en) | 2012-03-30 | 2012-05-16 | Agency Science Tech & Res | Bicyclic heterocyclic derivatives as mnk2 and mnk2 modulators and uses thereof |
| US8853207B2 (en) * | 2012-04-12 | 2014-10-07 | Development Center For Biotechnology | Heterocyclic pyrazole compounds, method for preparing the same and use thereof |
| MX2018006856A (es) | 2015-12-07 | 2018-08-01 | Plexxikon Inc | Compuestos y metodos para modulacion de la quinasa, e indicaciones de los mismos. |
-
2020
- 2020-08-21 TW TW109128678A patent/TWI759829B/zh active
- 2020-08-22 BR BR112022003383A patent/BR112022003383A2/pt unknown
- 2020-08-22 CN CN202080059010.6A patent/CN114502553B/zh active Active
- 2020-08-22 MX MX2022002062A patent/MX2022002062A/es unknown
- 2020-08-22 EP EP20856905.3A patent/EP4017853A4/en active Pending
- 2020-08-22 KR KR1020227009059A patent/KR20220051365A/ko active Pending
- 2020-08-22 AU AU2020337883A patent/AU2020337883B2/en active Active
- 2020-08-22 WO PCT/US2020/047552 patent/WO2021041276A1/en not_active Ceased
- 2020-08-22 JP JP2022511322A patent/JP7651557B2/ja active Active
- 2020-08-22 US US17/636,116 patent/US12448394B2/en active Active
- 2020-08-22 CA CA3151821A patent/CA3151821A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| JP2022545019A (ja) | 2022-10-24 |
| WO2021041276A1 (en) | 2021-03-04 |
| US12448394B2 (en) | 2025-10-21 |
| US20220289759A1 (en) | 2022-09-15 |
| CA3151821A1 (en) | 2021-03-04 |
| AU2020337883B2 (en) | 2025-08-28 |
| EP4017853A4 (en) | 2023-08-30 |
| BR112022003383A2 (pt) | 2022-05-17 |
| CN114502553B (zh) | 2024-07-26 |
| CN114502553A (zh) | 2022-05-13 |
| TW202115087A (zh) | 2021-04-16 |
| JP7651557B2 (ja) | 2025-03-26 |
| TWI759829B (zh) | 2022-04-01 |
| AU2020337883A1 (en) | 2022-03-24 |
| EP4017853A1 (en) | 2022-06-29 |
| KR20220051365A (ko) | 2022-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ECSP20067394A (es) | Inhibidores de cinasa dependientes de ciclina | |
| NI202100027A (es) | Inhibidores de la proteína tirosina fosfatasa | |
| MX2021014177A (es) | Inhibidores de kras con la mutacion de glicina a cisteina en el codon 12 (g12c) y usos de los mismos. | |
| CL2020000427A1 (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos. | |
| GEP20237453B (en) | Glp-1 receptor agonists and uses thereof | |
| CO2017000912A2 (es) | Derivados de 2 -h indazol como inhibidores de kinasas dependientes de ciclinas (cdk) y usos terapeuticos de los mismos | |
| AR097388A1 (es) | Beneficio de supervivencia en pacientes con tumores sólidos con niveles elevados de proteína c reactiva | |
| CL2020001576A1 (es) | Componentes heterocíclicos bicíclicos sustituidos como inhibidores de prmt5. | |
| AR088535A1 (es) | Derivados de amidas de aminoacidos sustituidos con n-urea como moduladores de receptor formil peptido del receptor del tipo 1 (fprl-1) | |
| MX2016010519A (es) | Moleculas para administracion a celulas cancerosas mutantes ros1. | |
| CO6970607A2 (es) | Moduladores del receptor mas acoplado a la proteína g y el tratamiento de trastornos relacionados con el mismo | |
| AR096543A1 (es) | INHIBIDORES DE QUINASA PI3 d Y g SELECTIVOS DUALES | |
| EA201790395A1 (ru) | Производные аминотриазина, подходящие для применения в качестве соединений-ингибиторов tank-связывающей киназы | |
| CL2019002900A1 (es) | Análogos de benzoazepina como agentes inhibidores de la tirosina cinasa de bruton. | |
| AR107061A1 (es) | Heteroarilhidroxipirimidinonas como agonistas del receptor de apj | |
| MX2019011904A (es) | Composicion farmaceutica que contiene agonista de mor y agonista de kor, y sus usos. | |
| BR112018075206A2 (pt) | tratamento de malignidade hematológica com 2-(4-clorofenil)-n-((2-(2,6-dioxopiperidin-3-il)-1-oxoisoindolin-5-il)metil)-2,2-difluoroacetamida | |
| AR094735A1 (es) | Benzamidas sustituidas con actividad hacia receptores ep4 | |
| ECSP17007208A (es) | Derivados de indano e indolina y el uso de los mismos como activadores de la guanilato ciclasa soluble | |
| SA519401322B1 (ar) | مركبات أريل كربوكساميد غير متجانسة كمثطبات لكيناز بروتين سيرين/ ثريونين متداخل مع المستقبل 2 | |
| PE20211246A1 (es) | Compuestos biciclicos para su uso como inhibidores de rip1 quinasa | |
| MX2021008263A (es) | Métodos de tratamiento de afecciones relacionadas con el receptor s1p1. | |
| CO6361991A2 (es) | Compuestos enlazados con azufre para el tratamiento de enfermedades y trastornos oftalmicos. | |
| CL2020001020A1 (es) | Derivados de bencimidazol y sus usos. | |
| PE20210096A1 (es) | Inhibidor de ret para uso en tratar cancer que tiene una alteracion de ret |